Chinese Medicine Neuroaid Efficacy on Stroke Recovery | Zendy

Christopher Chen | Zendy; Sherry H. Young | Zendy; Herminigildo H. Gan | Zendy; Rajinder Singh | Zendy; Annabelle Y. Lao | Zendy; Alejandro C. Baroque | Zendy; Hui Meng Chang | Zendy; John Harold B. Hiyadan | Zendy; Carlos Chúa | Zendy; Joel Advincula | Zendy; Sombat Muengtaweepongsa | Zendy; Bernard P.L. Chan | Zendy; H. Asita de Silva | Zendy; Somchai Towanabut | Zendy; Nijasri C. Suwanwela | Zendy; Niphon Poungvarin | Zendy; Siwaporn Chankrachang | Zendy; Ka Sing Wong | Zendy; Gaik Bee Eow | Zendy; Jose C. Navarro | Zendy; Narayanaswamy Venketasubramanian | Zendy; Chun Fan Lee | Zendy; M G Bousser | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chinese Medicine Neuroaid Efficacy on Stroke Recovery

Author(s) -

Christopher Chen,

Sherry H. Young,

Herminigildo H. Gan,

Rajinder Singh,

Annabelle Y. Lao,

Alejandro C. Baroque,

Hui Meng Chang,

John Harold B. Hiyadan,

Carlos Chúa,

Joel Advincula,

Sombat Muengtaweepongsa,

Bernard P.L. Chan,

H. Asita de Silva,

Somchai Towanabut,

Nijasri C. Suwanwela,

Niphon Poungvarin,

Siwaporn Chankrachang,

Ka Sing Wong,

Gaik Bee Eow,

Jose C. Navarro,

Narayanaswamy Venketasubramanian,

Chun Fan Lee,

M G Bousser

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.002055

Subject(s) - medicine , modified rankin scale , stroke (engine) , placebo , odds ratio , subgroup analysis , confidence interval , randomized controlled trial , physical therapy , adverse effect , clinical trial , stroke recovery , ischemic stroke , rehabilitation , ischemia , alternative medicine , mechanical engineering , pathology , engineering

Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research